Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

YM BioSciences Inc., announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Clues to molecular markers on breast tumors that may predict spread of lymph node cancer

Predicting breast cancer spread from a sentinel lymph node removed during surgery is a hit or miss affair, say researchers: there are still many false negatives, which means the node, when analyzed under a microscope, appears clean of cancer cells, but metastasis can still occur in the patient. The sentinel node is the first lymph node in the axilla that cancer spreads to.

19 Apr 2010

VisEn Medical expands FMT imaging platform

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models. VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR 101st Annual Meeting.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

Four-protein complex provides new target for thwarting cancer migration, invasion

The molecular machinery that switches on a gene known to cause breast cancer to spread and invade other organs has been identified by an international team led by scientists at The University of Texas M. D. Anderson Cancer Center. The paper was published Sunday in Nature Cell Biology's advanced online publication.

16 Apr 2010

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Genomic component playing key role in promoting breast cancer progression discovered

Life Technologies Corporation today announced that its scientists have teamed with researchers from Stanford University School of Medicine, and other institutions to discover a genomic component that plays a key role in promoting breast cancer progression. A study published today in the journal Nature details how levels of a specific kind of non-coding RNA molecule in primary breast tumors regulate metastasis and tumor invasiveness and may be an important target for cancer diagnosis and therapy.

15 Apr 2010

Study: New anti-cancer agents halt cancer metastasis

ke microscopic inchworms, cancer cells slink away from tumors to travel and settle elsewhere in the body. Now, researchers at Weill Cornell Medical College report in today's online edition of the journal Nature that new anti-cancer agents break down the loping gait these cells use to migrate, stopping them in their tracks.

15 Apr 2010

Stress hormones may suppress tumor growth: Study

Chronic stress triggers a chain of molecular events that protects breakaway ovarian cancer cells from destruction, a team of researchers led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 12 in the early online publication of the Journal of Clinical Investigation.

13 Apr 2010

Research shows association between LRP16 expression in colorectal cancer and disease related death

Leukemia related protein 16 gene is an important estrogen-responsive gene. LRP16 gene plays an important role in the carcinogenesis and progression of hormone-dependent cancer. LRP16 expression was also reported to be associated with invasion, metastasis and prognosis of gastric carcinoma. But no comprehensive description of LRP16 protein expression in colorectal cancer has been reported.

12 Apr 2010

Src can be most promising targets for cancer therapy

Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. Src represents one of the most promising targets for cancer therapy.

6 Apr 2010

UEA scientists discover group of molecules that can help fight spread of cancer

A team of scientists led by the University of East Anglia has discovered a brand new group of molecules which could help fight the spread of cancer and other diseases.

5 Apr 2010

A detailed review for managing solid pseudopapillary tumors

Solid pseudopapillary tumor (SPT) of the pancreas is a rare neoplasm with a low malignant potential, usually affecting young women in the second or third decade of life.

3 Apr 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

Researchers find Dpp protein causes metastatic tumour migration

One of the most intriguing questions in cancer research is what causes metastatic tumour migration, why some tumour cells manage to migrate to other parts of the body but others cells don't. International investigation conducted by Enrique Mart-n Blanco, CSIC researcher at the Institute of Biology of Barcelona, located in the Barcelona Science Park, reveals that cells make use of a natural mechanism for this.

30 Mar 2010

Development and validation process of Rosetta Genomics' miRview mets published

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces publication of an article describing the development and validation process of miRview™ mets, the company's microRNA-based test for identification of primary origin of metastases.

30 Mar 2010

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.

30 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Metastasis News and Research

Further Reading

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

Clues to molecular markers on breast tumors that may predict spread of lymph node cancer

VisEn Medical expands FMT imaging platform

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Four-protein complex provides new target for thwarting cancer migration, invasion

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Genomic component playing key role in promoting breast cancer progression discovered

Study: New anti-cancer agents halt cancer metastasis

Stress hormones may suppress tumor growth: Study

Research shows association between LRP16 expression in colorectal cancer and disease related death

Src can be most promising targets for cancer therapy

UEA scientists discover group of molecules that can help fight spread of cancer

A detailed review for managing solid pseudopapillary tumors

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Researchers find Dpp protein causes metastatic tumour migration

Development and validation process of Rosetta Genomics' miRview mets published

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News